Navigation Links
Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
Date:11/12/2008

tion of antibiotic therapy for each patient should be 7 to 14 days. The results of this study are expected in late 2009.

In completed Phase I studies in healthy subjects NXL104/ceftazidime was generally well tolerated and the pharmacokinetics of the two components were well matched. Additional studies in special populations are ongoing.

Iain Buchanan, Novexel's CEO, said, "We continue to believe that this novel combination, which is based around our novel beta-lactamase inhibitor, NXL104, has the potential to play an important role in confronting the increasing problem of hospital infections caused by resistant Gram negative bacteria. The start of our first Phase II study with NXL104 in combination with ceftazidime is an important milestone for the company."

Under an independent development program, Forest Laboratories (NYSE : FRX) will combine NXL104 in a treatment regimen with Forest's ceftaroline, a novel, bactericidal injectable broad spectrum cephalosporin being developed as a therapeutic agent for the treatment of gram-positive pathogens including methicillin resistant staphylococcus aureus (MRSA), and multi-drug resistant streptococcus pneumoniae (MDRSP), as well as common gram-negative organisms. Ceftaroline is being studied as a monotherapy in Phase III clinical trials by Forest. In January 2008, Novexel granted Forest a license to develop, manufacture and commercialise NXL104, only in combination with ceftaroline, in North America.

Novexel retains worldwide rights on the NXL104/ceftazidime combination.

About NXL104

NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics (penicillins, cephalosporins, carbopenems) mediated by beta-lactamase enzymes. NXL104 is a significant advance, as it is able to inhibit a broader range of beta-lactamases than currently marketed beta-lactam inhibitors. Its s
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
3. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
4. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
5. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
6. Particle Sciences Expands Its Combination Product Capabilities
7. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
8. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
11. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014  Lockton Dunning Benefits, the ... announced the addition of Vice President Kim ... Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... experience to the position.  Most recently, she worked ... Diplomat Specialty Pharmacy, where she has held various ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014  Endo ... ENDP ) (TSX: ENL), and BioDelivery Sciences ... that they have submitted a New Drug Application (NDA) ... and Drug Administration (FDA).  Buprenorphine HCl Buccal Film is ... to require daily, around-the-clock, long-term opioid treatment and for ...
(Date:12/22/2014)... Dec. 22, 2014 Apnea Sciences ( www.apneasciences.com ... in Aliso Viejo , California.  ... the tremendous growth and worldwide expansion, a new facility ... SnoreRx, the anti snore cure have exceeded our expectations ... "We are now in 23 countries and will be ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), ... today announced that BioSpecifics, President, Tom Wegman, will present ... 29th Annual Health Care Conference on Tuesday, March 17, ... Place in Boston, MA. A live webcast of the ...
... WASHINGTON, March 10 Despite the nation,s economic ... a record $65.2 billion last year in the ... vaccines - an increase of roughly $2 billion ... Research and Manufacturers of America (PhRMA) and Burrill ...
Cached Medicine Technology:R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 4
(Date:12/24/2014)... December 24, 2014 Verde Pointe Dental Associates ... ever. "Last years homemade Christmas sweater lit up, but ... The 2014 winner is Tandy Wilson for the second year ... enthusiast," says Kirk Kimmerling DDS. "She took pictures of the ... the sweater." , "Every year I enjoy stopping ...
(Date:12/24/2014)... NV (PRWEB) December 24, 2014 As ... reminds homeowners that before investing time and money ... consulting a licensed professional that specializes in tankless and ... plan to replace their water heater in 2015 to ... final decision. , Greenstar Home Services specializes in ...
(Date:12/24/2014)... Dennis Thompson HealthDay ... There,s good news about the experimental Ebola vaccine that U.S. ... research shows a precursor of that vaccine produced a ... version of the vaccine, when given to more than 100 ... and white blood cells that could potentially protect a person ...
(Date:12/24/2014)... Alan Mozes HealthDay Reporter ... using indoor tanning beds and booths, although this risky behavior remains ... survey reveals. In 2013, about 20 percent of high school ... some form of indoor tanning at least once in the previous ... 25 percent of girls and nearly 7 percent of boys who ...
(Date:12/22/2014)... Angeles, CA (PRWEB) December 22, 2014 ... names have changed. The reason why most fad diets ... - temporarily. The problem with fad diets is that, as ... tapers, leaving the dieter uncertain of how to reset the ... For this reason, Diet Doc developed their all-inclusive diet ...
Breaking Medicine News(10 mins):Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2Health News:Greenstar Home Services Offers Tankless Water Heater Advice to Local Homeowners 2Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4Health News:Fewer U.S. Teens in Tanning Salons, Study Finds 2Health News:Fewer U.S. Teens in Tanning Salons, Study Finds 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4
... US in 2005 from the fatal arrhythmias through devices which ... people in North America received this treatment. Quite a few ... and even dangerous. A noninvasive test has been developed recently ... benefit from the implantable cardiac defibrillator (ICD). ...
... major depressive disorder can get a temporary emotional lift through ... 40 men and women were studied before this conclusion was ... workout, but this can contribute towards giving them an emotional ... John Bartholomew has revealed that regular exercise could contribute towards ...
... has been a tenfold increase in the number of patients ... the last eight years. // During the year 2004 alone, ... Scotland alone, when compared to the 1997 figure of 10 ... ,The opposition party in the UK has ...
... vegetables are now being called the elixir of health. New ... eating more fruit and vegetables could let you live longer//. ... a day can reduce the risk of stroke by a ... levels of potassium, folate, fibre and antioxidants in fruit and ...
... Beer Ladybird Bio beer which contains various herbs and vitamins ... of takers, as the new beer does not increase obesity ... ,The beer, invented by Srinivasa Amarnath over 10 years, is ... head the next morning. It also uses the usual ingredients ...
... headed by Dr. Valentin Fuster between the Centro Nacional ... Sinai School of Medicine, for the benefit of cardiovascular ... 6 million has already been made by the CNIC ... to become a center of international excellence with regard ...
Cached Medicine News:
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... of medication as well as humidification, try ... dilution, high volume, continuous medication nebulizer (CMN), ... patients. Its 200 ml reservoir and jet ... hours of nebulized medication delivery at 25 ...
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only...
... Respiratory Products, ,Westmed designs, manufacturers and ... and Respiratory professionals. Our mission is to ... clinician's ability to deliver quality medical care ... line. , ,Our web site is ...
Medicine Products: